Eligibility Module
The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.
Eligibility Module path is as follows:
Study -> Protocol Section -> Eligibility Module
Eligibility Module
Ignite Creation Date:
2025-12-24 @ 9:56 PM
Ignite Modification Date:
2025-12-24 @ 9:56 PM
NCT ID:
NCT02651532
Eligibility Criteria:
Inclusion Criteria:
* Above 18 years old patients
* Who agree to participate in the study
* Ability to provide written informed consent
* Patients with irritable bowel syndrome according to Roma III classification.
Exclusion Criteria:
* Patients, who were receiving nonsteroidal anti-inflammatory drugs, corticosteroids or antibiotics in the last 4 weeks.
* Patients with heart disease, kidney, liver or severe metabolic disorder, who cannot tolerate sedation
* Inflammatory bowel disease
* Bacterial overgrowth
* Gastrointestinal bleeding
* Prior history of any king of colitis (actinic, infectious, ischemic, microscopic colitis)
* Suspected colonic obstruction or history of previous obstruction
* Prior history of colectomy surgery
* Patients with an ileostomy or a colostomy
* Patients with difficulty understanding instructions of bowel preparation
* Known allergy to fluorescein or shellfish
* Pregnancy and lactation
* Bowel preparation will be evaluated using the Boston Bowel Preparation Scale. (9) Patients with \< 2 points in at least one of the three segments of the colon (rectum plus left-side colon, transverse colon plus left and right flexure, right-side colon) will be excluded from statistical analysis as well as those who after the beginning of the colonoscopy, had to be aborted because of an inability to reach the cecum by unfavorable anatomy or impassable tumors / stenosis.
Healthy Volunteers:
False
Sex:
ALL
Minimum Age:
18 Years
Maximum Age:
80 Years
Study:
NCT02651532
Study Brief:
Protocol Section:
NCT02651532